Table 1.
Epidemiological and clinical features of 162 patients at the diagnosis of COVID-19. Group B: olfactory VAS score < 7; group A: olfactory VAS score ≥ 7. Values are reported as the median and IQR or percentage.
| Total Population | Group A | Group B | p Values | |
|---|---|---|---|---|
| No. of patients | 162 | 44 | 118 | |
| Age (years) | 57.0 (48.8–63.0) | 57.0 (51.0–64.0) | 56.0 (46.8–63.0) | 0.239 |
| Sex (female) | 80 (49.4%) | 27 (61.4%) | 55 (46.6%) | 0.113 |
| BMI | 26.9 (24.8–29.5) | 27.1 (25.1–30.1) | 26.7 (24.7–29.3) | 0.292 |
| Current smoker (n, %) | 33 (20.4%) | 10 (22.7%) | 23 (19.5%) | 0.665 |
| Infectious diseases (n, %) | 0 | 0 | 0 | - |
| Autoimmune diseases (n, %) | 22 (13.6%) | 12 (27.3%) | 10 (8.5%) | 0.004 |
| Hypertension (n, %) | 45 (27.8%) | 16 (36.4%) | 29 (24.6%) | 0.168 |
| Respiratory insufficiency (n, %) | 17 (10.5%) | 7 (15.9%) | 10 (8.5%) | 0.246 |
| Heart problems (n, %) | 61 (37.7) | 18 (40.9%) | 43 (36.4%) | 0.716 |
| Kidney insufficiency (n, %) | 6 (3.7%) | 4 (9.1%) | 2 (1.7%) | 0.047 |
| Allergies (n, %) | 10 (6.2%) | 1 (2.3%) | 9 (7.6%) | 0.108 |
| Comorbidities (n, %) | 89 (54.9%) | 28 (63.6%) | 61 (51.7%) | 0.215 |